Intellia Therapeutics to Present at October Healthcare Investor Conferences

September 30, 2019

CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both *in vivo* and *ex vivo*, will present at the following upcoming healthcare conferences in October:

Monday, October 7, 2019
Chardan 3rd Annual Genetic Medicines Conference
Location: New York, NY
Time: 9:00 am ET

Tuesday, October 8, 2019
Jefferies Gene Therapy/Editing Summit
Location: New York, NY
Time: 8:35 am ET

A live webcast of Intellia's presentations at the Chardan and Jefferies conferences will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia's website for approximately 14 days following each conference.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients' diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:
Lina Li
Associate Director
Investor Relations
+1 857-706-1612
lina.li@intelliatx.com

Media:
Jennifer Mound Smoter
Senior Vice President
External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com

Source: Intellia Therapeutics, Inc.